Together, these results suggest that FIH deletion promotes Amot accumulation, which in turn acts as a tumor suppressor in lung cancer, acting through the inhibition of downstream Hippo-YAP/TAZ signaling. The gene discussed is CASR; the disease is lung carcinoma.